Impax enrolls patients into late-stage trial for Parkinson’s treatment
HAYWARD, Calif. — The branded drugs division of Impax Labs has finished enrolling patients in a late-stage trial of a drug for Parkinson’s disease.
Impax Pharmaceuticals said Tuesday that it had enrolled patients in ASCEND-PD, a phase-3 trial of IPX066 that will compare the drug with carbidopa-levodopa and entacapone in patients with advanced Parkinson’s. IPX066 is an extended-release formulation of carbidopa-levodopa in capsule form.
“We are extremely pleased to have completed enrollment in ASCEND-PD, which is the third phase-3 trial of IPX066 in [Parkinson’s disease] subjects,” Impax Pharmaceuticals chief scientific officer Suneel Gupta said. “The study compares IPX066 to another commonly used medication in advanced PD and is intended to provide further safety and efficacy data on IPX066.”
Access, Walgreens broaden relationship to reach underserved populations
CHICAGO — Access Community Health Network and Walgreens have extended their relationship to co-develop an integrated program to provide accessible preventive and primary health care for underserved populations, Access said Monday.
As part of the partnership, Walgreens will work with Access on the following initiatives:
Create a pharmacy and therapeutics committee that will provide prescribing guidelines for all Access health centers to help every patient receive cost-effective, high-quality drug therapies;
Integrate a clinical pharmacy resident with Access’ physicians and nurses at one of Access’ health centers on Chicago’s South Side; and
Open a pharmacy inside the Access Genesis Center for Health and Empowerment health center in Des Plaines, Ill., which predominantly cares for an underserved Hispanic population.
Walgreens currently performs pharmacy services for Access’ more than 50 health centers that participate in the federal 340B program, which offers deep discounts on prescription medications to some of the nation’s most vulnerable patient populations, Access said.
"We are working with Walgreens to co-develop an integrated program that will ease the transition of our patients from in-patient facilities to enjoying healthy lives in the community and preventing hospital readmissions," Access CEO Donna Thompson said. "Through all of these Walgreens initiatives, Access will be better able to meet the needs of patients who often have nowhere else to turn for treatment."
Better glycemic control achieved among diabetics with authoritative parents, study finds
ALEXANDRIA, Va. — Children with Type 1 diabetes may achieve better blood-sugar control if their parents are more authoritative with them, a new study has found.
The study, conducted by researchers at the Israel Diabetes Center of Schneider Children’s Medical Center of Israel and published in the August issue of the journal Diabetes Care, found what they called an association between more authoritative parenting by fathers and better glycemic control in children, while a sense of hopelessness in fathers and mothers was associated with worse glycemic control and adherence. The study enrolled parents and children ages 11 years to 18 years.
More authoritativeness among fathers, but not mothers, was associated with better treatment adherence and glycemic controls, while children with more permissive mothers had worse adherence. Among boys, higher authoritarianism among mothers also was associated with less adherence.
“The findings may help healthcare providers and parents in determining appropriate parental involvement in the daily management of children’s and adolescents’ diabetes needs,” lead researcher Joseph Meyerovitch said. “The association between paternal level of authoritativeness and diabetes control measures highlights the importance of fathers’ involvement in children’s diabetes management. Unfortunately, our clinical experience along with empirical evidence suggests that when compared with mothers, fathers tend to take a too-small role in their child’s diabetes management.”